Tranilast (trans-) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.

PD 123319 ditrifluoroacetate is a novel, potent, and selective nonpeptide AT2 (angiotensin II) receptor antagonist with IC50 of 34 nM.

AVE-0991 is a novel, orally bioactive non-peptide mimic and high affinity agonist of angiotensin-(1-7) (IC50 o=21 nM) with important cardioprotective bioactivity.

Tranilast (also known as MK 341; SB 252218; trade name Rizaben), an analog of a tryptophan metabolite, is an antiallergic drug developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma.

Tasosartan (ANA-756, AC1Q6LAA, DB01349, WAY-ANA-756, Verdia) is a pyrido-pyrimidin-based and long-acting antagonist of angiotensin II (AngII) receptor with anti-hypertensive effects.

Olmesartan (formerly also known as CS-866) is a potent and selective angiotensin II type 1 (AT(1)) receptor antagonist used in the treatment of high blood pressure.

Sparsentan (formerly known as PS433540; BMS-346567; RE-021; DARA-a) is a novel, highly potent dual antagonist of angiotensin II and endothelin A receptor for the treatment of IgA nephropathy (IgAN).

Losartan (DuP-753) is a potent, selective, and non-peptide angiotensin II receptor antagonist, it competes with angiotensin II for binding to AT1 receptors with IC50 of 20 nM.

Losartan D4 carboxylic acid (EXP3174 D4; EXP 3174; EXP-3174) is the tetra-deuterated form of Losartan carboxylic acid, which is a cytochrome P450-mediated carboxylic acid metabolite, and is an active metabolite of Losartan.

Irbesartan HCl (formerly known as SR-47436 and BMS-186295) is a novel, highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.